Summary
Quest Diagnostics Incorporated (DGX) filed an 8-K on October 24, 2023, to announce its financial results for the quarter ended September 30, 2023. The filing primarily consists of a press release detailing these results. Investors should refer to the attached press release (Exhibit 99.1) for specific financial and operational performance metrics. This 8-K serves as the official notification of the company's performance during the third quarter of 2023. While the 8-K itself doesn't contain the detailed analysis, it directs stakeholders to the press release for the core information. Investors interested in understanding Quest Diagnostics' performance, including revenue, profitability, and any forward-looking statements or guidance, will need to examine the content of Exhibit 99.1. This filing is a standard procedure for publicly traded companies to promptly disclose material financial information.
Key Highlights
- 1Quest Diagnostics (DGX) filed an 8-K on October 24, 2023, reporting Q3 2023 financial results.
- 2The primary content of the filing is a press release (Exhibit 99.1) detailing the company's performance for the quarter ended September 30, 2023.
- 3Investors should consult the press release for specific financial metrics and operational updates.
- 4The filing confirms the timely disclosure of Q3 2023 results as per regulatory requirements.
- 5No specific financial figures are provided within the 8-K text itself, only a reference to the press release.